---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-004948"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T03:13:32.199102+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech gets safety committee nod for Phase 2 of Ampligen + Imfinzi in pancreatic cancer

## Summary
- Safety committee approved Phase 2 based on Phase 1 data: no severe adverse events or dose-limiting toxicities.
- Phase 2 enrollment expected to commence imminently; up to 25 patients to be enrolled.
- Combination therapy uses AIM's Ampligen and AstraZeneca's Imfinzi for late-stage pancreatic cancer.
- Phase 1 data showed combination generally well-tolerated; some patients had stable disease for 15+ months.

## SEC filing metadata
- accession: 0001493152-25-004948
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315225004948/0001493152-25-004948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315225004948/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-004948
- JSON: https://secwatch.observer/filing/0001493152-25-004948.json
- Plain text: https://secwatch.observer/filing/0001493152-25-004948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.